Browse by author
Lookup NU author(s): Professor Vijay KunadianORCiD, Dr Nina WilsonORCiD, Dr Deborah Stocken, Emerita Professor Elaine McCollORCiD, Dr Graham Burns, Nicola Howe, Professor Andrew FisherORCiD, Professor Anthony De SoyzaORCiD
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).
The APPLE COPD-ICON2 trial is a prospective 2×2 factorial, double-blinded proof-of-conceptrandomised controlled trial targeting patients with chronic obstructive pulmonary disease (COPD) without priorhistory of cardiovascular disease. The primary goal of this trial is to investigate if treatment with antiplatelet therapywill produce the predefined cut-off of platelet inhibition measured using the Multiplate test in COPD patients.Eligible patients were randomised to aspirin plus placebo, ticagrelor plus placebo, aspirin plus ticagreloror placebo only for 6 months. The primary outcome comprises inhibition (binary response) of arachidonicacid- (ASPI test, cut-off <40) and adenosine diphosphate- (ADP test, cut-off <46) induced plateletaggregation at 6 months.543 patients were screened and 120 patients were recruited with mean age of 67.5 years; 47.5% patientswere male. The per-protocol ASPI test response rate to aspirin was 68.3% (95% CI 52.3–80.9%). The perprotocolADP test response rate to ticagrelaor was 68.8% (95% CI 50.4–82.6%).Platelet response to antiplatelet therapy with aspirin and ticagrelor was not observed in nearly one-thirdof COPD patients without prior history of cardiovascular disease. These findings support the high prothromboticmilieu and the need for further research to determine the effect of antiplatelet/antithrombotictherapy on cardiovascular morbidity and mortality in COPD patients.
Author(s): Kunadian V, Wilson N, Stocken D, Hani A, McColl E, Burns G, Howe N, Fisher A, De Soyza A
Publication type: Article
Publication status: Published
Journal: ERJ Open Research
Year: 2019
Volume: 5
Issue: 3
Online publication date: 05/08/2019
Acceptance date: 11/06/2019
Date deposited: 29/10/2019
ISSN (electronic): 2312-0541
Publisher: European Respiratory Society
URL: https://doi.org/10.1183/23120541.00110-2019
DOI: 10.1183/23120541.00110-2019
Altmetrics provided by Altmetric
